UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
June 1, 2026
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F ☒
Form 40-F ☐
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 1 June 2026 –
On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the
European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe
Harbour Rules”). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month
period beginning 4 February 2026.
Under the programme initiated 6 May 2026,
Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.
Since the announcement 26 May 2026, the following
transactions have been made:
Number
of
B
shares
Average
purchase
price
Transaction
value,
DKK
Accumulated, last announcement
2,289,849
670,560,306
26 May 2026
210,000
288.13
60,506,846
27 May 2026
209,971
286.16
60,085,467
28 May 2026
210,180
287.85
60,500,695
29 May 2026
210,000
293.42
61,617,382
Accumulated under the programme
3,130,000
913,270,696
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated
above, Novo Nordisk owns a total of 35,074,480 B shares of DKK 0.10 as treasury shares, corresponding to 0.8% of the share capital. The
total amount of A and B shares in the company is 4,465,000,000 including treasury shares.
Page 2 of 2
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12month period beginning 4 February 2026. As of
29 May 2026, Novo Nordisk has since 4 February 2026 repurchased a total 17,889,179 B shares at an average share price of DKK 263.47 per
B share equal to a transaction value of DKK 4,713,270,686.
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat
serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our
medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its
products in around 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York
Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts
for further information
Media:
Ambre James-Brown
Liz Skrbkova
(US)
+45 3079 9289
+1 609 917 0632
globalmedia@novonordisk.com
lzsk@novonordisk.com
Investors:
Michael Novod
Jacob Martin
Wiborg Rode
+45 3075 6050
+45 3075 5956
nvno@novonordisk.com
jrde@novonordisk.com
Max Ung
Sina Meyer
+45 3077 6414
+45 3079 6656
mxun@novonordisk.com
azey@novonordisk.com
Alex Bruce
Christoffer
Sho Togo Tullin
+45 34 44 26 13
+45 3079 1471
axeu@novonordisk.com
cftu@novonordisk.com
Frederik Taylor Pitter
Mads Berner
Bruun
+1 609 613 0568
+45 3075 2936
fptr@novonordisk.com
mbbz@novonordisk.com
Novo Nordisk A/S
Investor Relations
Novo Allé 1
2880 Bagsværd
Denmark
Telephone:
+45 4444 8888
www.novonordisk.com
CVR no: 24 25 67 90
Company
announcement No 36 / 2026
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: June 1, 2026
NOVO NORDISK A/S
Maziar Mike Doustdar
Chief Executive Officer